The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
The finance leader and investment banking veteran to steer global financial strategy, investor relations, and growth initiatives
The company highlighted continued demand strength and pricing resilience despite global disruptions
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
